相关临床试验
0
0 进行中
药物批准
3
批准总数
监管机构
1
监管机构数
成立时间
2011
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Medipost has appointed Min Ho-sung, former Samsung Biologics executive vice president, as president to lead its global business push. - Min will oversee global clinical trials, overseas business development, and CDMO affiliate OmniaBio under a new co-CEO structure. - Cartistem's Phase 3 trial in Japan met both primary and secondary endpoints, with a Biologics License Application now being prepared. - A Phase 3 trial of Cartistem is also underway in the United States, positioning the stem cell therapy for global commercialization.
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- Rznomics, a South Korean RNA gene therapy developer, has joined Lilly Gateway Labs in San Diego to accelerate its trans-splicing ribozyme platform and pipeline of more than 200 disease targets. - The move grants Rznomics access to wet-lab facilities and direct engagement with Lilly scientists and executives, supporting preclinical and clinical development. - Rznomics and Eli Lilly signed a research collaboration and licensing agreement in May 2025, reported at approximately ₩1.9 trillion ($1.4 billion), to co-develop a novel RNA editing therapy. - Rznomics plans to establish U.S. clinical infrastructure, expand global partnerships, and recruit top-tier R&D talent as part of its long-term strategy.
- Samsung Biologics announced a $1.8 billion all-cash acquisition of Swiss CDMO PolyPeptide Group, the largest pharma M&A in South Korean history. - The deal expands Samsung's portfolio beyond antibodies, mRNA, and ADCs into peptides, including GLP-1 therapies for obesity and diabetes. - PolyPeptide Group brings six global sites, approximately 1,500 staff, and over 1,000 peptide development projects to Samsung's operations. - The global peptide CDMO market is projected to grow from $5.52 billion to $29.14 billion by 2035, driven by surging obesity treatment demand.
- The global automated liquid handling technologies market is projected to grow from US$2.7 billion in 2024 to US$7.4 billion by 2034 at a CAGR of 10.6%. - Drug discovery and ADME-Tox research accounted for the largest application segment at 41.9% of market share in 2023, with pharmaceutical and biotechnology companies representing 52.3% of end users. - North America leads the market with 39.5% of global revenue, while Asia Pacific is expected to register the fastest growth driven by expanding R&D investments. - Integration of artificial intelligence, machine learning, and cloud-enabled laboratory automation is enhancing workflow optimization and data management capabilities across the sector.
- The global biosimilar market expanded fifteen-fold from US$2.2 billion in 2016 to roughly US$32.7 billion in 2024, with Korea and India serving as its manufacturing engine room. - Despite record revenues at Celltrion, Samsung Bioepis, and Biocon, APAC manufacturers face a structural "value trap" where US pharmacy benefit managers capture the economic upside through private-label biosimilars. - The FDA is dismantling interchangeability requirements, proposing to eliminate comparative clinical efficacy studies, which simultaneously lowers development costs and erodes product differentiation. - Some 118 biologics worth US$232 billion in US sales lose exclusivity through 2034, yet only 10% have a biosimilar in active development, revealing a "biosimilar void" driven by poor return economics.
- Samsung Biologics returns for its 14th consecutive year, showcasing 845,000 liters of total manufacturing capacity and its newly acquired Rockville, Maryland plant. - Celltrion marks its 17th appearance with a dedicated AI zone, promoting AI-driven drug discovery, antibody conjugates, and multispecific antibodies as next-generation growth engines. - For the first time, BIO International Convention hosts an official Korea-focused session titled "Korea Rising: Don't Be Late to Asia's Next Innovation Hub." - Over 20,000 attendees from more than 70 countries are expected, with 51 Korean companies presenting pipelines and platform technologies at the KoreaBio country pavilion.
- The global fill-finish manufacturing market reached roughly US$11 billion in 2025, with more than US$27 billion committed to expanding sterile capacity across 2024–2025 alone. - The GLP-1 boom has displaced non-GLP-1 sterile products from existing filling lines, forcing sponsors of antibodies, vaccines, and specialty injectables to seek new manufacturing partners. - Asia-Pacific is building isolator-first, device-aware fill-finish capacity faster than any other region, though equipment qualification lead times of 12–18 months mean most expansions will not be operational until 2027–2028. - The revised EU GMP Annex 1 has raised the regulatory floor globally, making the Contamination Control Strategy a mandatory, inspection-ready system that directly constrains throughput and batch risk.
- The global continuous bioprocessing market was valued at USD 386.89 million in 2025 and is forecast to grow at a CAGR of 17.44% through 2034. - Monoclonal antibodies accounted for the largest application segment at 35.94% market share in 2025, reflecting the dominance of mAb manufacturing. - North America led the market with a 38.65% revenue share in 2025, while Asia Pacific is expected to grow fastest at a 19.10% CAGR. - Key industry developments include Thermo Fisher's $4.0 billion acquisition of Solventum's Purification & Filtration business in September 2025.
- Formycon AG announced a strategic partnership with ATHOS KG valued at approximately €650 million, marking one of the most significant developments in the German biotech company's history. - The collaboration grants Formycon participation rights in two biosimilar candidates, accelerating time-to-market while reducing clinical and regulatory risk compared to in-house development. - The deal structure includes upfront payments, milestone fees tied to regulatory approvals, and commercial royalties, representing a fundamental shift in Formycon's capital allocation strategy. - Biosimilars command higher margins than generic pharmaceuticals due to sophisticated manufacturing requirements and regulatory complexity, positioning Formycon in an attractive market segment driven by patent expirations and healthcare cost containment.
